DGAP-News: Vita 34 AG / Key word(s): Quarter Results14.05.2020 / 07:30 The issuer is solely responsible for the content of this announcement.
Business development of Vita 34 stable and unaffected by COVID-19 development so far
Leipzig, 14 May 2020 - Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), one of the largest cell banks in Europe, has made a stable start to the new 2020 financial year. Revenues in the first quarter remained almost at the previous year's level. In the second quarter, the current order intake also shows a linear sales development so far. To secure the supply of production-relevant preliminary products, sufficient precautions have been taken to prevent negative effects on process stability in connection with the COVID-19 pandemic.
At EUR 4.7 million, revenues in the first quarter were 2.3 percent below the previous year (Q1 2019: EUR 4.8 million). As a result of the targeted increase in marketing and sales expenses by approximately nine percent to EUR 1.4 million compared to the prior-year period (Q1 2019: EUR 1.3 million), earnings before interest, taxes, depreciation and amortization (EBITDA) were down 9.9 percent to EUR 1.2 million (Q1 2019: EUR 1.3 million). "In the past financial year we analyzed how to deploy our budgets in an even more targeted manner in order to achieve organic growth in our core market," explains Dr. Wolfgang Knirsch, CEO of Vita 34 AG. "Accordingly, we have increased our marketing and sales expenses in certain areas in order to accelerate our organic growth and further consolidate our leading market position."
The company's liquidity situation remains very positive. At EUR 9.1 million, cash and cash equivalents were at the same level as at the end of 2019 (31.12.2019: EUR 9.1 million). "The changed environment, which came as a surprise to us with the COVID-19 pandemic in the first quarter of 2020, required extraordinary efforts at all levels. Due to the still difficult assessable range of the effects of the pandemic, the focus of the measures was on maintaining core processes. From today's perspective, we have achieved this. It is therefore all the more pleasing that despite the expansion of working capital that was necessary in certain areas, liquidity was maintained at a high level," explains Falk Neukirch, CFO of Vita 34 AG.
The key figures for business development in the first quarter of 2020 are as follows:
Since the beginning of May, the company has also been able to return to addressing the relevant target groups personally in the market. "It goes without saying that we are exercising the utmost caution in dealing with this special situation," explains CFO Falk Neukirch. "As things stand at present, however, we are making good progress through these challenging times."
According to Chinese scientists, it should be possible to successfully treat critical COVID-19 pneumonia with the help of connective tissue stem cells, so-called mesenchymal stem cells from umbilical cord tissue. Since these cells are chemotactic, they migrate specifically to sites of inflammation, trigger regeneration processes and weaken the inflammatory reaction. This approach has now been taken up and positively evaluated in a specialist publication of the Harvard Medical School. This supportive therapy is currently being investigated in 19 clinical studies in Asia and Europe. "The results of most of these studies will not be available until later this year", explains CEO Dr. Wolfgang Knirsch, "If the results are positive, we expect that the regenerative potential of stem cells from umbilical cord blood and umbilical cord tissue will again receive increased attention".
Against the background of the stable business development in the first quarter and the previous indication for the second quarter, the Management Board of Vita 34 continues to adhere to its forecasts for the financial year 2020.
Contact:Ingo MiddelmenneInvestor RelationsVita 34 AGPhone: +49 (0341) 48792 - 0Mobile: +49 (0174) 9091190Email: ingo.middelmenne@vita34.de
Company ProfileVita 34 was founded in Leipzig in 1997 and is today one of the leading cell banks in Europe. As the first private umbilical cord blood bank in Europe and a pioneer in cell banking, the company has since then been a complete provider of cryopreservation services for the collection, processing and storage of stem cells from umbilical cord blood and umbilical cord tissue. Based on the expansion of the business model in 2019, Vita 34 intends to also offer the storage of immune cells from peripheral blood as well as of stem cells from endogenous fat in the future. Nursing cells are a valuable source of medical cell therapy and are kept alive at temperatures as low as minus 200 degrees Celsius to be used as part of a treatment when needed. More than 237,000 customers from more than 20 countries have already provided for their family's health with a cell depot at Vita 34.
14.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de
View post:
Business development of Vita 34 stable and unaffected by COVID-19 development so far - PharmiWeb.com
- The Firsthand Results Of A Nanofat Treatment Using Stem Cells And PRP - Forbes - November 16th, 2024
- Eat These 5 Underrated Foods To Boost Metabolism, Says An MD - mindbodygreen - November 16th, 2024
- BioRestorative Therapies IFATS 2024 Presentation to - GlobeNewswire - September 21st, 2024
- Fasting may help improve immune system; 3 reasons why one should fast at least once a week or a month - Times Now - February 24th, 2023
- Alpilean Weight Loss Reviews (Legit Or Fake) Dont Try Alpine Ice Hack Diet Before You See This! - Outlook India - February 24th, 2023
- Stevens Institute of Technology Professors Use Interdisciplinary Collaboration to Enhance the Field of 3D-Printed Tissues - India Education Diary - February 24th, 2023
- Stress can throw off circadian rhythms and lead to weight gain - Medical News Today - August 19th, 2022
- Scientists Aim to Bring the Tasmanian Tiger Back From Extinction Mother Jones - Mother Jones - August 19th, 2022
- Benefits Of Ozone Therapy In Pain Medicine - Nation World News - August 19th, 2022
- New Discovered Adipokines Associated with the Pathogenesis of Obesity | DMSO - Dove Medical Press - August 11th, 2022
- Slimvance Reviews - Does This Fat Burner Really Work? - Outlook India - August 11th, 2022
- Mesenchymal stem cells - PubMed - June 16th, 2022
- Stem cells: Sources, types, and uses - Medical News Today - June 16th, 2022
- Fat Cells - The Definitive Guide | Biology Dictionary - June 16th, 2022
- Stem Cells For Back Pain | Stem Cells For Herniated Discs - June 16th, 2022
- 2022-06-13 | OTCPK:BRTXD | Press Release | BioRestorative Therapies - Stockhouse - June 16th, 2022
- Hepatic Diseases and Associated Glucose Intolerance | DMSO - Dove Medical Press - June 16th, 2022
- Why Fitness Experts Are Obsessed With "Bulletproofing" the Body - InsideHook - June 16th, 2022
- New Stem cell conveying hydrogel could assist the heart with recuperating myocardial ischemia - Microbioz India - August 17th, 2021
- Participants Diagnosis Halts Gene Therapy Clinical Trial - The Scientist - August 17th, 2021
- The Involuted Palate, or the Savage Crinkle of Future Snacks - lareviewofbooks - August 17th, 2021
- Time to Go Sushi With Cellular Salmon; When Pet Owners Tire of Their Minions - The SandPaper - August 17th, 2021
- Adipose-derived Stem Cell Market Analysis, Key Company Profiles, Types, Applications and Forecast To 2027 The Courier - The Courier - May 27th, 2021
- Global Cell Therapy Markets, Technologies, and Competitive Landscape Report 2020-2030: Applications, Cardiovascular Disorders, Cancer, Neurological... - May 27th, 2021
- What is lab grown meat? A scientist explains the taste, production and safety of artificial foods - BBC Focus Magazine - May 27th, 2021
- Rheumatoid Arthritis Stem Cell Therapy Market share, growth drivers, demand, supply, challenges, and investment opportunities by 2028 - WhaTech - May 27th, 2021
- Obesity-Related Inflammation and Endothelial Dysfunction in COVID-19: | JIR - Dove Medical Press - May 27th, 2021
- The hunt for the master cow that will feed the world - Wired.co.uk - May 27th, 2021
- Australia's Magic Valley On How to Turn Cells From "Cell Volunteer" Lucy the Lamb Into Lamb Steaks and Chops - vegconomist - the vegan... - May 27th, 2021
- Clearing Cellular Dead Wood | In the Pipeline - Science Magazine - May 27th, 2021
- University of Pittsburgh Won't Explain its Planned Parenthood Ties | Opinion - Newsweek - May 27th, 2021
- Smart Stem Cells Made From Fat Have the Power to Heal - Freethink - February 14th, 2021
- Network-based screen in iPSC-derived cells reveals therapeutic candidate for heart valve disease - Science - February 14th, 2021
- Their Goal: Meat That's Better Than Meat | Tufts Now - Tufts Now - January 31st, 2021
- Gut microbiota: How does it interact with the brain? - Medical News Today - December 30th, 2020
- The 10 Best Herbs for Liver Health: Benefits and Precautions - Healthline - December 19th, 2020
- Startups are racing to reproduce breast milk in the lab - MIT Technology Review - December 19th, 2020
- The facts about the danger of melanoma - The Hudson Reporter - December 19th, 2020
- And Now, a Moment for Culture(d Meat) - The Spoon - December 4th, 2020
- How to live longer: Calorie restriction may reset your biological body clock - Express - December 4th, 2020
- Future Meat is cutting costs on mass production with an unlikely cellular approach - The Spoon - November 30th, 2020
- BioRestorative Therapies Emerges from Chapter 11 Reorganization - OrthoSpineNews - November 25th, 2020
- The Adipose Tissue Derived Stem Cells market to grow in the wake of incorporation of the latest technology - The Think Curiouser - November 7th, 2020
- Global Cell Therapy Technologies, Competitive Landscape & Markets, 2019-2020 & Forecast to 2029 - ResearchAndMarkets.com - Yahoo Finance - November 7th, 2020
- Blocking energy pathway reduces GVHD while retaining anti-cancer effects of T-cells - Science Codex - November 7th, 2020
- Singapore startup Shiok Meats re-creates shrimp in the lab - Los Angeles Times - October 10th, 2020
- Aqua-Spark Announces an Investment in Singapore-based Shiok Meats, the First Cell-Based Company to Produce Clean, Sustainable, Cruelty-Free Shrimp and... - October 6th, 2020
- Orgenesis to acquire regenerative medicine company Koligo Therapeutics - Pharmaceutical Business Review - September 30th, 2020
- Heart attack patches may save lives in US and beyond - Galveston County Daily News - September 30th, 2020
- Orgenesis Announces Agreement to Acquire Koligo Therapeutics, a Leader in Personalized Cell Therapies - GlobeNewswire - September 30th, 2020
- Bariatric surgery is booming, as obese patients worry about their Covid-19 risks - The Daily Briefing - September 30th, 2020
- Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027) - Unica News - September 30th, 2020
- Regenerative medicine and war: The next breakthrough in treating injured veterans? - Genetic Literacy Project - September 29th, 2020
- Sherrie Hewson celebrates 70th birthday with second face lift to transform her looks - The Sun - September 15th, 2020
- Two Austin Women Hope to Build the First Lab-Grown Brisket - Texas Monthly - September 15th, 2020
- FDA Clears Jointechlabs' MiniTC for Point-of-Care Fat Tissue Processing and its Broad Range of Applications - PRNewswire - August 26th, 2020
- Photos That Reveal the Hidden Side of Things - Obsev - August 26th, 2020
- Research Roundup: Lasting Immunity to COVID-19 and More - BioSpace - August 25th, 2020
- The Truth About Cosmetic Treatments review a format in need of a facelift - The Guardian - August 25th, 2020
- Survivors of Pediatric Cancers May Experience Lasting Impact on Heart, Metabolic Health Following Radiation Therapy - Pharmacy Times - August 15th, 2020
- AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update - Business Wire - August 15th, 2020
- Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027) - Good Night, Good Hockey - August 15th, 2020
- Meet The 12 Next-Gen Food Techs Transforming The Future Of Protein - Green Queen Media - August 15th, 2020
- Meat-lover who wants to save the planet? 3D printed steaks are your solution - ThePrint - July 12th, 2020
- Fat stem cells improve prognosis in patients with Covid-19 ... - July 11th, 2020
- Making Sense of Stem Cells and Fat Grafting in Plastic ... - July 11th, 2020
- Tip Sheet: SARS-CoV-2 antibodies, COVID-19 and health disparities, eating in tough times and immune protection in breast milk - Fred Hutch News... - July 9th, 2020
- Blood factors transfer beneficial effects of exercise on neurogenesis and cognition to the aged brain - Science Magazine - July 9th, 2020
- Fasting is not starvation or a fad, it is a discipline: Luke Coutinho - The Indian Express - July 9th, 2020
- Is Meat Grown in a Lab Really Meat? - The New York Times - July 7th, 2020
- What if mammoths are brought back from extinction? - The Economist - July 7th, 2020
- Cancer Stem Cells (CSCs) Market Recent Industry Developments and Growth Strategies Adopted by Players - Cole of Duty - July 1st, 2020
- Coronavirus symptoms: How COVID-19 can damage the brain - what to look for - Express - July 1st, 2020
- Westerleigh resident is alive because of stem cell therapy by his doctor -- for free. Heres his story. - SILive.com - June 13th, 2020
- Regenerative Therapy Options for Horses With Osteoarthritis - TheHorse.com - June 13th, 2020
- Fat cells remember their diets early in life - Massive Science - June 13th, 2020
- Patient uses fat stem cells to repair his wrist - CNN - June 10th, 2020
- FDA Warns About Stem Cell Therapies | FDA - June 10th, 2020
- Regenerative Therapies: Helping Horses Self-Heal The Horse - TheHorse.com - May 31st, 2020
- AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A -... - May 31st, 2020